On 16 January 2014, orphan designation (EU/3/13/1212) was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for ibrutinib for the treatment of follicular lymphoma.
|Disease / condition||
Treatment of follicular lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.